EVH Evolent Health, Inc. - 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders

(a)     Evolent Health, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) on June 4, 2026. At the 2026 Annual Meeting, the Company’s stockholders voted on four proposals. The proposals are described in the Company’s definitive proxy statement on Schedule 14A for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 24, 2026.

(b)     The final voting results with respect to each proposal voted upon at the 2026 Annual Meeting are set forth below.

Proposal 1

The Company’s stockholders elected ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company’s 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below:

For

Against

Abstentions

Broker

Non-Votes

Toyin Ajayi, MD

60,373,601

5,912,292

90,502

15,840,303

Craig Barbarosh

65,818,775

467,147

90,471

15,840,305

Seth Blackley

60,323,961

5,993,625

58,810

15,840,302

Russell Glass

60,316,659

5,982,067

77,670

15,840,302

Peter Grua

60,324,441

5,961,459

90,496

15,840,302

Shawn Guertin

65,881,893

396,849

97,653

15,840,303

Richard Jelinek

60,027,846

6,269,584

78,965

15,840,303

Kim Keck

60,178,555

6,131,979

65,860

15,840,304

Jill Smith

65,919,489

402,133

54,773

15,840,303

Brendan Springstubb

65,810,202

468,292

97,900

15,840,304

Proposal 2

The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026 as set forth below:

For

Against

Abstentions

82,036,843

124,362

55,493

Proposal 3

The Company’s stockholders approved the compensation of our named executive officers for 2025 on an advisory basis, as set forth below:

For

Against

Abstentions

Broker

Non-Votes

58,369,473

7,922,802

84,119

15,840,304

Proposal 4

The Company’s stockholders approved the amendment to the Amended and Restated 2015 Omnibus Incentive Compensation Plan, as set forth below:

For

Against

Abstentions

Broker

Non-Votes

47,536,873

18,712,636

126,885

15,840,304